PE20120501A1 - L-asparaginasa tratada con peg - Google Patents

L-asparaginasa tratada con peg

Info

Publication number
PE20120501A1
PE20120501A1 PE2012000023A PE2012000023A PE20120501A1 PE 20120501 A1 PE20120501 A1 PE 20120501A1 PE 2012000023 A PE2012000023 A PE 2012000023A PE 2012000023 A PE2012000023 A PE 2012000023A PE 20120501 A1 PE20120501 A1 PE 20120501A1
Authority
PE
Peru
Prior art keywords
peg
asp
conjugate
asparaginase
polyethylene glycol
Prior art date
Application number
PE2012000023A
Other languages
English (en)
Inventor
Thierry Abribat
Original Assignee
Alize Pharma Ii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alize Pharma Ii filed Critical Alize Pharma Ii
Publication of PE20120501A1 publication Critical patent/PE20120501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN CONJUGADO QUE COMPRENDE UNA L-ASPARAGINASA DE ERWINIA QUE TIENE AL MENOS UN 80% DE IDENTIDAD CON EL AMINOACIDO DE SEQ ID NO:1 Y POLIETILENGLICOL, DONDE DICHO CONJUGADO TIENE LA FORMULA Asp-[NH-CO-(CH2)x-CO-NH-PEG]n. Asp ES L-ASPARAGINASA, PEG ES EL POLIETILENGLICOL, NH ES UNO O MAS DE LOS GRUPOS NH DE LOS RESIDUOS DE LISINA Y/O EL N-TERMINAL EN LA Asp, n ES UN NUMERO QUE REPRESENTA ENTRE 40% Y 100% DE GRUPOS AMINO ACCESIBLES EN LA Asp Y x ES UN ENTERO DE ENTRE 1 Y 8. DICHO CONJUGADO TIENE ACTIVIDAD AMINOHIDROLASA DE L-ASPARAGINA Y ES UTIL EN EL TRATAMIENTO DEL CANCER, PARTICULARMENTE LEUCEMIA LINFOBLASTICA AGUDA
PE2012000023A 2009-07-06 2010-07-06 L-asparaginasa tratada con peg PE20120501A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22332009P 2009-07-06 2009-07-06
PCT/EP2010/054156 WO2011003633A1 (en) 2009-07-06 2010-03-30 Pegylated l-asparaginase

Publications (1)

Publication Number Publication Date
PE20120501A1 true PE20120501A1 (es) 2012-05-31

Family

ID=42232655

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016001555A PE20161325A1 (es) 2009-07-06 2010-07-06 L-asparaginasa tratada con peg
PE2012000023A PE20120501A1 (es) 2009-07-06 2010-07-06 L-asparaginasa tratada con peg

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016001555A PE20161325A1 (es) 2009-07-06 2010-07-06 L-asparaginasa tratada con peg

Country Status (26)

Country Link
US (6) US20120100121A1 (es)
JP (1) JP6014956B2 (es)
KR (1) KR101731999B1 (es)
CN (1) CN102573917B (es)
AU (1) AU2010270294B2 (es)
BR (1) BR112012000367A2 (es)
CA (1) CA2767149C (es)
CO (1) CO6612174A2 (es)
DK (1) DK2451486T4 (es)
EA (1) EA021168B1 (es)
ES (1) ES2636476T5 (es)
FI (1) FI2451486T4 (es)
HK (1) HK1173092A1 (es)
HU (1) HUE035771T2 (es)
IL (1) IL217392A (es)
IN (1) IN2012DN00958A (es)
LT (1) LT2451486T (es)
MA (1) MA33503B1 (es)
MX (1) MX2012000424A (es)
MY (1) MY180758A (es)
NZ (1) NZ597912A (es)
PE (2) PE20161325A1 (es)
PT (1) PT2451486T (es)
SG (1) SG176984A1 (es)
UA (1) UA104634C2 (es)
WO (2) WO2011003633A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE531779C2 (sv) * 2007-11-26 2009-08-04 Promimic Ab Framställning av kalciumfosfatpartiklar i nanostorlek som pulver eller beläggning via bifunktionella prekursorer
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
WO2015033344A1 (en) 2013-09-05 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
US20160213759A1 (en) * 2013-09-10 2016-07-28 Board Of Regents, The University Of Texas System Therapeutic asparaginases
CN104046600B (zh) 2013-12-30 2019-04-05 江苏众红生物工程创药研究院有限公司 多臂聚乙二醇修饰剂的新用途及其在修饰门冬酰胺酶中的应用
BR102014000585B1 (pt) 2014-01-10 2021-01-12 Coppe/Ufrj-Instituto Alberto Luiz Coimbra De Pós-Graduação l-asparaginase recombinante de zymomonas
US9808011B2 (en) 2014-12-15 2017-11-07 Biovectra Inc. Pentacyclic triterpene compounds and uses thereof
CN105802948B (zh) * 2014-12-29 2020-06-09 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用
WO2017055484A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the metabolic status of lymphomas
WO2017151707A1 (en) * 2016-03-01 2017-09-08 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
MY198474A (en) 2016-06-01 2023-08-31 Servier Ip Uk Ltd Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2018085493A1 (en) * 2016-11-04 2018-05-11 Georgia State University Research Foundation, Inc. Endotoxin free asparaginase
EP3642340B1 (en) * 2017-06-21 2024-03-20 Jazz Pharmaceuticals Ireland Limited Modified l-asparaginase
EP3418383A1 (en) * 2017-06-21 2018-12-26 XL-protein GmbH Modified l-asparaginase
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
WO2019083793A1 (en) * 2017-10-27 2019-05-02 Pfenex Inc. PROCESS FOR THE PRODUCTION OF RECOMBINANT ERWINIA ASPARAGINASE
EP3701036A4 (en) 2017-10-27 2021-09-01 Pfenex Inc. METHOD OF MANUFACTURING RECOMBINANT E. COLI
SG11202004965RA (en) * 2017-11-30 2020-06-29 Jazz Pharmaceuticals Ireland Ltd Methods of treatment with asparaginase
JP2021520828A (ja) * 2018-04-19 2021-08-26 キンドレッド バイオサイエンシズ インコーポレイテッド 医療用の変異体アスパラギナーゼポリペプチド
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
GB201912020D0 (en) * 2019-08-21 2019-10-02 Porton Biopharma Ltd Therapeutic Conjugate
EP4048303A1 (en) * 2019-10-25 2022-08-31 Jazz Pharmaceuticals Ireland Ltd. Recombinant l-asparaginase
KR102269634B1 (ko) * 2019-10-31 2021-06-25 대상 주식회사 ansB 유전자 불활성화에 의해 아미노산 생산능력이 향상된 균주
EP4267592A1 (en) 2020-12-23 2023-11-01 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins
WO2022211829A1 (en) 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2024008659A1 (en) 2022-07-04 2024-01-11 Institut National de la Santé et de la Recherche Médicale Use of a l-asparaginase in combination with a ferroptosis inducer for the treatment of extranodal natural killer/t-cell lymphoma
WO2024015529A2 (en) 2022-07-14 2024-01-18 Jazz Pharmaceuticals Ireland Ltd. Combination therapies involving l-asparaginase

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9017002D0 (en) 1990-08-02 1990-09-19 Health Lab Service Board Improved method for the purification of erwina l-asparaginase
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5776746A (en) 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
AU2002332371A1 (en) * 2001-08-22 2003-03-10 Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatelsky Institut Biomeditsinskoy Khimii Im. Orekhovicha Recombinant l-asparaginase less thanigreater thanerwinia caratovoraless than/igreater than
JP2006523211A (ja) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
WO2007103290A2 (en) 2006-03-03 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
US20090167164A1 (en) 2006-04-21 2009-07-02 Konica Minolta Holdings, Inc. Gas barrier film, resin base for organic electroluminescent device, organic electroluminescent device using the same, and method for producing gas barrier film
ES2519466T3 (es) * 2007-03-09 2014-11-07 Novozymes A/S Asparaginasas termoestables
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof

Also Published As

Publication number Publication date
SG176984A1 (en) 2012-01-30
ES2636476T5 (es) 2023-06-01
KR20120104154A (ko) 2012-09-20
US20200347374A1 (en) 2020-11-05
JP2012532185A (ja) 2012-12-13
US20210348151A1 (en) 2021-11-11
ES2636476T3 (es) 2017-10-05
IN2012DN00958A (es) 2015-04-10
CN102573917A (zh) 2012-07-11
IL217392A (en) 2017-06-29
USRE49736E1 (en) 2023-11-28
DK2451486T3 (en) 2017-08-28
UA104634C2 (en) 2014-02-25
MA33503B1 (fr) 2012-08-01
CN102573917B (zh) 2015-06-17
US20180346900A1 (en) 2018-12-06
MX2012000424A (es) 2012-07-23
CA2767149A1 (en) 2011-01-13
EA201270134A1 (ru) 2012-07-30
JP6014956B2 (ja) 2016-10-26
PE20161325A1 (es) 2016-12-30
CA2767149C (en) 2019-11-26
EA021168B1 (ru) 2015-04-30
PT2451486T (pt) 2017-08-09
AU2010270294B2 (en) 2015-06-25
US20120100121A1 (en) 2012-04-26
HK1173092A1 (en) 2013-05-10
CO6612174A2 (es) 2013-02-01
LT2451486T (lt) 2017-11-10
BR112012000367A2 (pt) 2018-01-02
MY180758A (en) 2020-12-08
WO2011003886A1 (en) 2011-01-13
US20160060613A1 (en) 2016-03-03
FI2451486T4 (fi) 2023-04-25
IL217392A0 (en) 2012-02-29
HUE035771T2 (en) 2018-05-28
US9920311B2 (en) 2018-03-20
DK2451486T4 (da) 2023-04-17
AU2010270294A1 (en) 2012-02-23
US11046946B2 (en) 2021-06-29
NZ597912A (en) 2014-01-31
KR101731999B1 (ko) 2017-05-11
WO2011003633A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
PE20120501A1 (es) L-asparaginasa tratada con peg
CY1123169T1 (el) Συνθεσεις για αντιμετωπιση της mpsi
ES2619322T3 (es) Agente inductor de inmunidad
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
ES2723050T3 (es) Variantes de fitasa termoestables
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
EA201001628A1 (ru) Модифицированные полипептиды фактора vii и их применение
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
ECSP15042898A (es) Péptidos y composiciones para el tratamiento de daño articular
ES2627117T3 (es) Método basado en MGMT para obtener un rendimiento elevado de expresión de proteínas recombinantes
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
CR20150196A (es) Moléculas de unión il-17a novedosas y usos médicos de las mismas
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
BR112013004436A2 (pt) composições e usos de materiais com atividade microbicida alta e toxicidade baixa
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
MX2023000804A (es) Peptidos para usarse en la promocion del transporte de glucosa.
PH12017502323A1 (en) Novel xylanase
CL2009001249A1 (es) Uso de una enzima pectonilitica endopoligalacturonasa para tratar pure de frutas o verduras; procedimiento para tratamiento enzimatico; molecula de adn que codifica un polipeptido con actividad endopoligalacturonasa; polipeptido, vector de expresion y celula huesped que comprende dicha secuencia.
IN2014DN06121A (es)
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
MX2015013263A (es) Conjugados de hemoglobina oxido de polialquileno valerato.
CL2023001816A1 (es) Parapoxvirus modificado que tiene inmunogenicidad incrementada
ES2421407T3 (es) Agente y composición para la curación de heridas

Legal Events

Date Code Title Description
FC Refusal